Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
KNSA Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: May 01, 2026
Report Source: 2026 1st Quarter Report
Kiniksa Pharmaceuticals International PLC. Stock Analysis KNSA
United States Health Care Mid Cap Report: Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Read More Kiniksa Pharmaceuticals International PLC (KNSA) Chart
Key Statistics of Kiniksa Pharmaceuticals International PLC (KNSA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$57.00Volume
771.81KP/E Ratio (TTM)
74.4952 Week Range
Market Cap
4.13BAvg. Volume
564.90KDividend Yield
-Financial Metrics & Statements of Kiniksa Pharmaceuticals International PLC (KNSA)
FAQ's for Kiniksa Pharmaceuticals International PLC (KNSA)
- According to Musaffa’s Shariah screening methodology, Kiniksa Pharmaceuticals International PLC (KNSA) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kiniksa Pharmaceuticals International PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kiniksa Pharmaceuticals International PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kiniksa Pharmaceuticals International PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kiniksa Pharmaceuticals International PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kiniksa Pharmaceuticals International PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.